Organon and Medarex form biotherapeutics collaboration
Organon, the human health care business unit of Akzo Nobel, and Medarex are to collaborate on the development of fully human antibody therapeutics for the treatment of cancer and auto-immune disorders.
Organon, the human health care business unit of Akzo Nobel, and Medarex are to collaborate on the development of fully human antibody therapeutics for the treatment of cancer and auto-immune disorders.
Using Medarex's UltiMAb Human Antibody Development System and Netherlands-based Organon's expertise in drug discovery and development, the two companys plan to share the development and commercialisation responsibilities on any antibody-based therapeutics resulting from this collaboration, and to share revenues generated from the sale of such products. The financial terms were not disclosed.
David Nicholson, executive vice president r&d at Organon said: "We have recently increased our efforts in Cambridge, Massachussetts, to identify novel biologicals which will be effective treatments for auto-immune and oncological disorders, this additional collaboration with Medarex represents a further step towards becoming a very effective biological drug hunting company,"
Organon is seeking to leverage its position as a leading biopharmaceutical company in each of its core therapeutic fields: fertility, gynecology and selected areas of anesthesia.
Medarex, based in New Jersey, US, has more than 30 therapeutic product candidates in human clinical testing or have had INDs submitted for such trials, with six of the most advanced product candidates currently in Phase III clinical trials.
